Effects on recurrence and quAlity-of-life of iliac vein Stenting angioplasTy for patients with Varicose veins combined with severE Iliac veiN compression: a protocol for a prospective, multicentre, randomised clinical trial (EAST-VEIN trial) Authors: Longlong Cong, Fanggang Cai, Yaowen Chang, Zhaohui Hua, Zhipeng Hu, Huaxin Hao, Jiancang Ma, Lei Ma, Liang Wang, Liang Wang, Yin Xia, Huijun Yuan, Weifeng Yu, Feng Zhang, Hui Zhuang, Ruipeng Zhang, Zhang Zhang, Tao Yang, Lin Yang Published: 2025 ABSTRACT AbstractIntroductionBoth varicose veins (VV) and iliac vein compression syndrome (IVCS) can cause skin damage and functional impairment in the lower extremities, and these issues often coexist. However, the question of whether IVCS exacerbates VV progression and leads to differences in the surgical outcomes of therapy for VV remains unanswered. Therefore, no high-level evidence-based medical data is available to support the concomitant use of iliac vein stenting in patients with VV and severe IVCS, and treatment protocols vary significantly among different centres. This study will investigate the effects of concomitant iliac vein stenting on post-procedure varices recurrence and quality of life (QoL) on the basis of a prospective, multicentre, randomised controlled trial with the goal of providing a foundation for the standardised treatment of patients with VV and IVCS.Methods and analysisThis prospective, multicentre, randomised controlled trial will enrol 160 patients with VV and severe IVCS. All patients will be randomly divided into either the VV endovenous thermal ablation (ETA) alone group or the VV ETA combined with iliac vein stenting (ETAS) group. Baseline data will be collected and follow-up will be conducted at 1, 6, 12 and 36 months after the procedure. The primary outcome is post-procedure VV recurrence (as assessed by clinical and ultrasound examination). Secondary outcomes include QoL scores (according to the Aberdeen Varicose Vein Questionnaire, the Chronic Lower Limb Venous Insufficiency Questionnaire, the European Quality of Life Five-Dimensions, and the Venous Clinical Severity Score) and the incidence of post-procedure complications. Bleeding complications resulting from anticoagulation therapy and stent-related complications (such as restenosis and deep vein thrombosis) will also be recorded for patients in the ETAS group.Ethics and disseminationThis study has been approved by the Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong University (approval number: XJTU1AF2024LSYY-075). Written informed consent has been obtained from all participants. The final results of this study will be published in a peer-reviewed journal and presented at national or international conferences.Trial registration numberThis protocol was registered on chictr.org.cn prior to enrolment, which began on 19 June 2024 (Registration ID: ChiCTR2400085815).Keywords: Cardiovascular Disease, Clinical Protocols, Clinical Trial, Vascular medicine, Interventional radiology, Vascular surgery STRENGTHS AND LIMITATIONS OF THIS STUDY The multicentre, randomised, controlled design enhances methodological rigour and the generalisability of the study findings. The multicentre, randomised, controlled design enhances methodological rigour and the generalisability of the study findings. Patient selection will be strictly based on clinical classification and imaging criteria to ensure inclusion of a population with appropriate indications. Patient selection will be strictly based on clinical classification and imaging criteria to ensure inclusion of a population with appropriate indications. Study quality and patient safety will be ensured through rigorous systematic training, regular review and ongoing procedure monitoring. Study quality and patient safety will be ensured through rigorous systematic training, regular review and ongoing procedure monitoring. Clinical endpoints and multiple quality of life questionnaires can comprehensively assess endpoint events. Clinical endpoints and multiple quality of life questionnaires can comprehensively assess endpoint events. As an open-label study, potential bias and deviation cannot be completely eliminated. As an open-label study, potential bias and deviation cannot be completely eliminated. Introduction Background and rationale Varicose veins (VV) of the lower extremities are the most common vascular disease, with a prevalence of 10%–30% that increases with age, especially in specific populations and regions.1,3 Endovenous thermal ablation (ETA) procedures (such as endovenous laser ablation (EVLA) and radiofrequency ablation (RFA)) represent the first-line therapy recommended by different guidelines because they are minimally invasive and lead to better long-term outcomes.4,7 Iliac vein compression syndrome (IVCS) refers to a series of symptoms caused by iliac vein compression by surrounding tissues (ie, bone, artery, etc), resulting in venous reflux and obstruction, such as venous insufficiency, varices, skin pigmentation, ulcers and even deep vein thrombosis, which mostly involves the left iliac vein.8 9 Moreover, a previous report revealed that patients with VV often have varying degrees of IVCS.10 However, the pathogenesis and aetiology of VV and IVCS remain unclear, thus leading to confusion in therapeutic strategies: some experts report that simply treating VV without addressing iliac vein stenosis could improve the quality of life (QoL) of the patient,11 12 and some experts believe that simultaneous treatment of iliac vein stenosis and VV is necessary to achieve better long-term outcomes.13 14 Moreover, for patients with VV combined with IVCS, some experts believe that different therapeutic strategies should be selected on the basis of the clinical, etiologic, anatomic, and pathophysiologic (CEAP) classification.15 Therefore, the therapeutic strategy for VV combined with severe IVCS remains unclear, and new evidence-based medical data are urgently needed. The conclusions of retrospective studies from different centres have been characterised by obvious contradictions and controversies. Some previous studies have reported that after iliac vein stenting angioplasty to relieve iliac vein outflow obstruction, the reflux of the great saphenous vein (GSV) and the small saphenous vein (SSV) is significantly reduced, and the QoL of the patient is significantly improved, without the need for VV endovenous procedures16 17; however, other researchers have claimed that for patients with severe IVCS and VV, merely relieving iliac vein stenosis or occlusion does not significantly improve the main vein reflux or venous hypertension, and endovenous VV procedures are still needed.18 Simultaneous therapy for IVCS and VV can significantly improve the prognosis and QoL of the patient.13 14 Other studies have shown that simultaneous treatment not only does not result in additional benefits but also increases the risk of related complications due to long-term anticoagulation.19 20 Owing to the lack of high-quality, high-level evidence from prospective, randomised controlled trials, the current guidelines are still inconclusive in terms of their therapeutic recommendations for VV combined with IVCS.21 Therefore, we designed this multicentre, prospective, randomised controlled trial with the aim of providing clear evidence-based medical data to determine whether patients with VV and severe IVCS need iliac vein stenting angioplasty. Objectives The primary objective of this trial is to compare the recurrence rate of VV at different time points (1 and 3 years after the procedure) in patients with VV and severe IVCS treated with venous thermal ablation alone (ETA group) and ETA combined with iliac vein stenting (ETAS group), aiming to determine the ability of iliac vein stenting to reduce recurrence. The secondary objectives will be to evaluate the differences in the QoL by using the Aberdeen Varicose Vein Questionnaire (AVVQ), Chronic Lower Limb Venous Insufficiency Questionnaire (CIVIQ) and European Quality of Life Five-Dimensions (EQ-5D) scales, and changes in symptoms will be evaluated by using the Venous Clinical Severity Score (VCSS) to explore the differences between the two groups at different time points (1 month, 6 months, 1 year and 3 years after the procedure). The incidence of complications (including ablation-related complications and stenting-related complications) will also be recorded and analysed. Methods The following information follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) reporting guidelines.22 Study design This study is a prospective, multicentre, randomised controlled trial that will use a parallel group, non-double-blind design. The study process will proceed as follows: patients will be screened according to strict inclusion criteria on admission, complete baseline examinations and pre-procedure evaluations, and then will be randomly assigned to either the ETA or ETAS group. Post-procedure follow-up and data collection will be performed as planned. Study setting This study will be conducted in 18 hospitals across 9 provinces in China. The study centres are as follows: The First Affiliated Hospital of Xi’an Jiaotong University The First Affiliated Hospital of Fujian Medical University, Fuzhou, China The First Affiliated Hospital of Lanzhou University, Lanzhou, China The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China The General Hospital of Ningxia Medical University, Yinchuan, China The First People’s Hospital of Baiyin, Baiyin, China The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China The Xi’an Ninth Hospital, Xi’an, China The Chengdu First People’s Hospital, Chengdu, China The Dongguan People’s Hospital, Dongguan, China The Fujian Provincial People’s Hospital, Fuzhou, China Xi’an Honghui Hospital of Xi’an Jiaotong University, Xi’an, China The Baoji Central Hospital, Baoji, China The 215 Hospital of Shaanxi Nuclear Industry, Xianyang, China The Xiamen Cardiovascular Hospital of Xiamen University, Xiamen, China The Shaanxi Provincial People’s Hospital, Xi’an, China The Second Affiliated Hospital of Air Army Medical University, Xi’an, China The Bethune Hospital of Shanxi Medical University, Taiyuan, China Participants This trial enrolling patients with VV of the lower extremities and severe ipsilateral IVCS diagnosed at 18 target hospitals starting in June 2024. All participants will sign informed consent forms before the procedure. Inclusion criteria Age range: 18–75 years, with no gender restrictions. Age range: 18–75 years, with no gender restrictions. Symptomatic VV (CEAP classification C3–C6). Symptomatic VV (CEAP classification C3–C6). Severe ipsilateral iliac vein stenosis (CT venography (CTV) or digital subtraction angiography (DSA) showing iliac vein stenosis ≥70%). Severe ipsilateral iliac vein stenosis (CT venography (CTV) or digital subtraction angiography (DSA) showing iliac vein stenosis ≥70%). GSV reflux time ≥0.5 s and diameter <15 mm. GSV reflux time ≥0.5 s and diameter <15 mm. The surgeon must have had experience of ≥200 cases. The surgeon must have had experience of ≥200 cases. Exclusion criteria History of ipsilateral lower limb VV surgery. History of ipsilateral lower limb VV surgery. History of ipsilateral lower limb venous thromboembolism. History of ipsilateral lower limb venous thromboembolism. Double GSV and iliac vein stenosis <70%. Double GSV and iliac vein stenosis <70%. GSV diameter >15 mm. GSV diameter >15 mm. Isolate SSV insufficiency. Isolate SSV insufficiency. Lower limb venous malformation, infection or severe limb arteriosclerosis obliterans (ankle-brachial index <0.8). Lower limb venous malformation, infection or severe limb arteriosclerosis obliterans (ankle-brachial index <0.8). Allergy to compression stockings. Allergy to compression stockings. Refusal to participate in the study. Refusal to participate in the study. Randomisation and blinding Commercial randomisation software will be used to generate the randomisation sequence; all patients will be assigned to the ETA and ETAS groups in a 1:1 ratio. The randomisation protocol will be maintained by an independent statistician, and the investigators will receive the group assignment information at enrolment. Because the interventions (iliac vein stenting in the ETAS group) differ significantly and iliac vein stenting is not the routine procedure for patients with IVCS and VV, it is not possible to blind the investigators and patients; however, the data analysts will be blinded. Description of the intervention After all potential patients have completed imaging examinations and pre-procedure screening and signed informed consent forms (figure 1), the patients in the ETA group will undergo standard endovenous thermal ablation (EVLA or RFA, in which context each centre will decide which thermal ablation procedure to use) for the VV under tumescent anaesthesia. The procedure will follow a standard protocol with ultrasound-guided catheter placement at the proximal end of the GSV. Laser and radiofrequency thermal ablation will then be performed under tumescent anaesthesia to close the GSV trunk above the knee. Ultrasound-guided foam sclerotherapy and point phlebectomy will be performed on the varices below the knee and tributaries. Subsequently, a conventional compression bandage will be applied for 72 hours, followed by the use of compression stockings for 3 months (daytime use only).23 24 Trial flowchart. AE, adverse events; AVVQ, Aberdeen Varicose Vein Questionnaire; CIVIQ, Chronic Lower Limb Venous Insufficiency Questionnaire; EQ-5D, European Quality of Life Five-Dimensions; IVCS, iliac vein compression syndrome; VCSS, Venous Clinical Severity Score; VV, varicose veins. In addition to ETA therapy, patients in the ETAS group will undergo concurrent iliac vein stenting (within a 1-month interval between procedures, regardless of order) under local anaesthesia with lidocaine. Briefly, iliac venography will be performed via bilateral femoral vein access. After the stenosis site is identified, a self-expanding dedicated venous stent (Venovo, Becton, Dickinson and Company, Tempe, Arizona, USA; diameter selected on the basis of vessel diameter) will be implanted on the affected side, and post-dilation will be determined on the basis of stent morphology. Residual stenosis of less than 30% and disappearance of the collateral circulation will be considered to indicate technique success. Postoperative anticoagulation (rivaroxaban 10 mg/day) will be initiated for 6 months, followed by long-term oral aspirin 100 mg/day.21 25 Primary outcome The primary outcome of the study is the clinical recurrence of varices, which is defined as the appearance of new VV in the original treated area during the follow-up period; recurrence will be assessed at 1 and 3 years after the procedure.26 27 Secondary outcomes The secondary outcomes will include the following: The QoL of patients in both groups will be assessed with three questionnaires: (1) The AVVQ,28 which assesses the impact of symptoms on daily life, in which total scores range from 0 to 35 and higher scores indicate worse QoL; (2) the CIVIQ,29 which is a QoL questionnaire specific to venous disease, in which total scores range from 0 to 100 and higher scores indicate worse QoL; and (3) the EQ-5D,30 31 which is used to assess the health status and QoL of an individual, in which total scores range from −0.391 to 1 and lower scores indicate worse QoL. Each patient will be required to complete the VCSS at baseline and during the follow-up period to assess the severity of venous disease of the patient.32 The VCSS score includes symptoms, signs and functional impairment, for a total of 10 items, each of which is scored as 0 (none), 1 (mild), 2 (moderate) or 3 (severe). The total score ranges from 0 to 30, and a higher score indicates worse venous disease. Post-procedure complications Postoperative complications include complications related to thermal ablation and iliac vein stenting. Complications of thermal ablation procedures include induration, haematoma, skin burns, phlebitis, numbness, deep vein thrombosis, etc.33 Complications related to iliac vein stenting include stent-related thrombosis, stent fracture, stent migration and bleeding events (minor bleeding is defined as skin and mucosal bleeding that resolves on its own without any medical therapy; major bleeding is defined as bleeding that requires medical intervention34). Patency of the stent The patency of the iliac stent is defined by uninterrupted flow within the vein without evidence of residual stenosis or compression.35 Restenosis will be determined by an independent ultrasonography team and will be defined as a diameter reduction >50%.36 Trial timescales On the basis of the prevalence of VV with severe IVCS, the patient volume seen by each centre, and relatively strict inclusion criteria, this study is expected to be completed in approximately 36 months (figure 2, additional file 1. SPIRIT checklist for trial). Trial protocol. The baseline and follow-up questionnaires of these trials, including the schedule of enrolment, interventions and assessments. AVVQ, Aberdeen Varicose Vein Questionnaire; CIVIQ, Chronic Lower Limb Venous Insufficiency Questionnaire; EQ-5D, European Quality of Life Five-Dimensions; ETA, endovenous thermal ablation; ETAS, endovenous thermal ablation+iliac vein stenting; VCSS, Venous Clinical Severity Scale. Baseline The research committee will require each centre to assign two dedicated medical staff members to collect research information and manage patient follow-up arrangements. One investigator will be responsible for collecting all relevant information, while the other will be responsible for assessing questionnaire quality and patient compliance during follow-up. All the investigators will receive unified training prior to the official start of the study. At baseline, demographic, baseline and procedure data will be collected from each patient. Additionally, phone or social media information from the patient or guardian will be collected to facilitate follow-up appointments. Patients will complete quality-of-life questionnaires (AVVQ, CIVIQ and EQ-5D) and clinical symptom scores (CEAP and VCSS) and will subsequently receive outpatient follow-up at 1 month, 6 months, 1 year and 3 years after the procedure. Follow-up Patients will be required to undergo outpatient follow-up at 1 month, 6 months, 1 year and 3 years after the procedure and will be required to complete quality-of-life questionnaires (AVVQ, CIVIQ and EQ-5D) and the Venous Clinical Severity Score (VCSS). Investigators will also ask about post-procedure complications and outcomes. Duplex ultrasound will be performed for participants in both groups to determine the occlusion or recurrence of the target vein. Iliac vein ultrasound will be performed on patients in the ETAS group to detect restenosis of the iliac vein stent at 12 months; we recommend that patients undergo the ultrasound examination again at 36 months to assess the long-term outcomes of iliac vein stent. If patients experience significant symptom recurrence, CTV or DSA examinations will be performed to facilitate further evaluation. Patients unable to complete outpatient follow-up will receive follow-up online either by telephone or on social media platforms. Sample size On the basis of the results of our previous retrospective study, published meta-analyses and statistical expert recommendations,11 13 37 38 the 1-year post-procedure recurrence rate in the ETA-alone group is expected to be approximately 18%–22% (the target value is defined as 0.19), and the recurrence rate of such symptomatic varices is expected to be 3.5% in the ETAS group (the target value is defined as 0.04). With a power of 90% and 5% (bilateral) significance equivalence, the calculated minimum number of cases is approximately 68 patients in one group. Given a 20% potential loss to follow-up rate, we plan to enrol 80 patients per group, for a total sample size of 160 patients. All patients will receive follow-up for at least 1 year after enrolment, and the study duration is planned to be 36 months. Recruitment Participants will be recruited from inpatients at each centre, and those who meet the inclusion criteria (after imaging assessment) will be informed of their possible participation in this study and will be provided with relevant information from their medical files. Patients who are interested in participating in the study will have a screening visit scheduled with the investigator/physician. After a detailed medical history is taken and detailed imaging examinations (CTV or DSA) are performed, if the potential participant meets the criteria and is willing to continue participating in the trial, the patient or the patient’s guardian will be asked to sign an informed consent form. The patient or the guardian will also be informed of the complete information about the trial process, therapy methods, risks, financial compensation (ultrasound follow-up costs) and follow-up of this study. Patients may voluntarily withdraw from the study at any stage; if they do not cooperate with follow-up, violate the randomisation principle or suffer serious complications, the investigator may decide to terminate their participation. Statistical analysis Once all patients have completed their follow-up, we will first conduct a preliminary analysis of the 12-month follow-up data (12-month recurrence, QoL and stent restenosis) of all participants. Data on the effect of the two procedures on long-term recurrence and QoL will be analysed at 36 months. All the data obtained from each centre will be entered into a database by a data entry staff member and saved in an Excel spreadsheet. These data will then be reviewed by a dedicated staff member to ensure data accuracy. Continuous variables will be tested for normality, normally distributed variables will be presented as the mean±SD, and intergroup comparisons will be performed by using Student’s t-test. Non-normally distributed variables will be presented as medians (IQRs), and the Kruskal‒Wallis test will be used for comparisons. Categorical variables will be presented as the number of cases (percentage), and intergroup comparisons will be performed on the basis of the χ2 test or Fisher’s exact test. Data will initially be analysed using the intention-to-treat (ITT) method, regardless of whether patients receive randomised treatment. The data will also be analysed via the per-protocol (PP) method. Differences will be considered clinically significant only if both the ITT and the PP analyses exhibit a consistent statistically significant trend. Recurrence will be analysed by using Kaplan‒Meier survival curves and the log-rank test. A value of p<0.05 will be considered to indicate statistical significance. All the data will be analysed via SPSS V.21.0 software (IBM Corporation, Armonk, New York, USA). Data collection and confidentiality To encourage participants to actively cooperate and complete all follow-up visits, investigators will be required to obtain the mobile phone number or social media account of each participant or guardian. Investigators will contact participants by phone or social media before each follow-up visit to remind them to attend. For participants who fail to attend their scheduled follow-up visits, outpatient appointments or examinations will be rescheduled within 1 week (or these participants will receive an online follow-up visit). Investigators will inquire about post-procedure complications and their assessment of their QoL to determine whether a second intervention or trial discontinuation is necessary. Participants will be assigned a unique trial identification number on the basis of their enrolment sequence. Data entry will be performed by trained data entry personnel to ensure quality, and all data will be collected anonymously. All the information collected during this study, including electronic and paper questionnaires, will be collected and securely stored in dedicated data storage cabinets at each centre for at least 10 years. Data collected during the study will be maintained in line with strict confidentiality agreements and will be accessible only to trial team members. Data monitoring, safety and quality control The ethics committees at each centre will regularly review the trial conduct (once every June or December), the trial management team will meet monthly to review the trial conduct, and the trial steering group and data monitoring committee will meet regularly throughout the trial to review its conduct. An adverse event (AE) is an untoward medical occurrence that occurs in clinical study subjects, which may or may not be related to the investigational device; all AEs should be recorded. A severe AE (SAE) is an undesirable and unexpected medical event or effect resulting in death or life-threatening consequences, specifically indicating a risk of death for the subject at the time of the event. This study will summarise device-related AEs, procedure-related AEs, AEs related to post-procedure antithrombotic medication therapy and serious AEs. Any SAE should be reported promptly to the Research Ethics Committee and sent by fax or email to the principal investigator within 24 hours of occurrence; the principal investigator and clinical events committee will then determine whether the event is ‘related’ (ie, caused by the study procedure) or ‘unexpected’ (ie, not listed as anticipated in the protocol). Investigators and sponsors at each centre will make every effort to prevent potential harm as a result of this study design. If any harm occurs related to this study, the clinical research institution and investigators will provide timely and adequate treatment and management according to routine clinical care and will bear the corresponding treatment costs. Data publication and reproducible research The final results of this study will be published in a peer-reviewed journal. The datasets and statistical codes analysed during the study will be made available from the corresponding author on reasonable request. Availability of data and materials All the data analyses and materials generated as part of this research are available on request. Withdrawal and termination Patients may withdraw from the study at any stage. While all the investigators at each centre will make every effort to ensure that the participants complete the study, voluntary withdrawal will not be discouraged. Ethics and dissemination This study has been approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University (approval number: XJTU1AF2024LSYY-075). Written informed consent has been obtained from all participants. The final results of this study will be published in a peer-reviewed journal and presented at national or international conferences. Informed consent procedures The participant informed consent form (Chinese original and English translation) is provided as supplemental material (onlinesupplemental files 1 2). Protocol amendments All protocol amendments must be submitted in writing to the ethics committee for reapproval. On approval, the principal investigator will notify all sites, retain copies of the revised protocol and update the revised protocol with the clinical trial registry. If the informed consent form is revised during the trial, the revised protocol must be reapproved by the ethics committee before implementation. After protocol approval is obtained, all subjects who have not yet completed the trial will be asked to sign the updated informed consent form. Discussion To address the therapeutic confusion and controversy concerning patients with VV and severe IVCS, this prospective randomised controlled trial will investigate the necessity of concurrent iliac vein stenting during the treatment of VV. In this study, the effects of iliac vein stenting on long-term recurrence and QoL in patients with VV and severe IVCS will be comprehensively evaluated on the basis of medium-term to long-term follow-up data. This study will be conducted at 18 representative, high-volume regional medical centres, resulting in a sufficient sample size for the trial. We will compare the recurrence rates and quality-of-life scores between patients who receive a combination of endovenous thermal ablation with iliac vein stenting (ETAS group) and those who receive endovenous VV thermal ablation (ETA group) alone. Compared with the ongoing DEep VEin Lesion OPtimisation (DEVELOP) trial (the first trial to assess the role of iliac vein intervention combined with standard surgical treatment in the treatment of venous ulcers),39 our study includes non-ulcer patients (C3–C4), making the study population more general. This study will provide high-level evidence to inform clinical guidelines and hopefully promote the development of standardised therapeutic strategies for VV and severe IVCS, thereby preventing undertreatment or overtreatment. Furthermore, the results of this study may help optimise medical resource allocation and develop more precise endovenous treatment plans for patients with both VV and IVCS, thereby reducing unnecessary procedures and their associated risks. Analysis of primary and secondary endpoints will provide data on the necessity, safety, patency, complications and risks of anticoagulation for iliac vein stenting, thereby providing essential data support for future updates to guidelines and relevant research. However, this study has several potential limitations. The non-blinded design may lead to assessment bias, but standardised procedures and objective measures (eg, ultrasound and scale scores) could partially mitigate this effect on the results. The ETAS group requires long-term anticoagulation or antiplatelet therapy, which may increase the risk of bleeding and reduce the rate of endovascular closure of the GSV, thus necessitating close monitoring during follow-up. Trial status The first version of the study was registered on chictr.org.cn (https://www.chictr.org.cn/showproj.html?proj=231238) on 19 June 2024. The current protocol is V.2.0, on 30 June 2024. Recruitment began on 6 July 2024 and is expected to conclude in July 2026. We expect to complete the trial in July 2027. Supplementary material Acknowledgements We thank the staff at all the participating centres and the patients who will be included in this trial and American Journal Experts for editing the language of this article. Footnotes Funding: This study is supported by the Horizontal Project of the First Affiliated Hospital of Xi'an Jiaotong University (HXIIT2024013). The funders will play no role in the design of the study; the collection, analysis or interpretation of the data, or the writing of the manuscript. Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2025-109837). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Consent obtained from parent(s)/guardian(s). Ethics approval: This study was approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University (approval number: XJTU1AF2024LSYY-075). Written informed consent was obtained from all participants. Participants gave informed consent to participate in the study before taking part. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. References Supplementary Materials Data Availability Statement All the data analyses and materials generated as part of this research are available on request.